Published in Toxicol Mech Methods on May 01, 2011
Epigenetic disorders and altered gene expression after use of Assisted Reproductive Technologies in domestic cattle. Epigenetics (2014) 0.94
From hepatitis to hepatocellular carcinoma: a proposed model for cross-talk between inflammation and epigenetic mechanisms. Genome Med (2012) 0.93
Role of epigenetic alterations in the pathogenesis of Barrett's esophagus and esophageal adenocarcinoma. Int J Clin Exp Pathol (2012) 0.92
MicroRNAs in cancer diagnosis and therapy: from bench to bedside. Surg Today (2012) 0.90
Investigation of the expression patterns and correlation of DNA methyltransferases and class I histone deacetylases in ovarian cancer tissues. Oncol Lett (2012) 0.88
Expression and clinicopathological significance of EED, SUZ12 and EZH2 mRNA in colorectal cancer. J Cancer Res Clin Oncol (2014) 0.88
CDH1 methylation in preoperative peritoneal washes is an independent prognostic factor for gastric cancer. J Surg Oncol (2012) 0.88
Expanding epigenomics to archived FFPE tissues: an evaluation of DNA repair methodologies. Cancer Epidemiol Biomarkers Prev (2014) 0.87
DNA promoter methylation as a diagnostic and therapeutic biomarker in gallbladder cancer. Clin Epigenetics (2012) 0.87
Plant phytochemicals as epigenetic modulators: role in cancer chemoprevention. AAPS J (2013) 0.86
Diet, the gut microbiome, and epigenetics. Cancer J (2014) 0.84
Dietary Glucosinolates Sulforaphane, Phenethyl Isothiocyanate, Indole-3-Carbinol/3,3'-Diindolylmethane: Anti-Oxidative Stress/Inflammation, Nrf2, Epigenetics/Epigenomics and In Vivo Cancer Chemopreventive Efficacy. Curr Pharmacol Rep (2015) 0.83
An epigenetic marker panel for recurrence risk prediction of low grade papillary urothelial cell carcinoma (LGPUCC) and its potential use for surveillance after transurethral resection using urine. Oncotarget (2014) 0.80
Cancer chemoprevention by traditional chinese herbal medicine and dietary phytochemicals: targeting nrf2-mediated oxidative stress/anti-inflammatory responses, epigenetics, and cancer stem cells. J Tradit Complement Med (2013) 0.79
A quantitative analysis of histone methylation and acetylation isoforms from their deuteroacetylated derivatives: application to a series of knockout mutants. J Mass Spectrom (2013) 0.77
Tumor suppressor gene BLU is frequently downregulated by promoter hypermethylation in myelodysplastic syndrome. J Cancer Res Clin Oncol (2012) 0.76
MTHFR C677T polymorphisms are associated with aberrant methylation of the IGF-2 gene in transitional cell carcinoma of the bladder. J Biomed Res (2012) 0.76
Evaluation of Methylation Biomarkers for Detection of Circulating Tumor DNA and Application to Colorectal Cancer. Genes (Basel) (2016) 0.76
SET oncoprotein accumulation regulates transcription through DNA demethylation and histone hypoacetylation. Oncotarget (2017) 0.75
Bioinformatics of Cancer ncRNA in High Throughput Sequencing: Present State and Challenges. Front Genet (2012) 0.75
Brassica-Derived Plant Bioactives as Modulators of Chemopreventive and Inflammatory Signaling Pathways. Int J Mol Sci (2017) 0.75
MicroRNAs: genomics, biogenesis, mechanism, and function. Cell (2004) 198.59
MicroRNAs: target recognition and regulatory functions. Cell (2009) 92.17
Chromatin modifications and their function. Cell (2007) 55.98
Oncomirs - microRNAs with a role in cancer. Nat Rev Cancer (2006) 46.47
MicroRNA signatures in human cancers. Nat Rev Cancer (2006) 46.29
Crystal structure of the nucleosome core particle at 2.8 A resolution. Nature (1997) 44.55
A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci U S A (2006) 40.09
MicroRNA targeting specificity in mammals: determinants beyond seed pairing. Mol Cell (2007) 38.42
Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci U S A (2008) 33.65
The impact of microRNAs on protein output. Nature (2008) 32.39
Mutation and cancer: statistical study of retinoblastoma. Proc Natl Acad Sci U S A (1971) 31.05
The epigenomics of cancer. Cell (2007) 30.91
The fundamental role of epigenetic events in cancer. Nat Rev Genet (2002) 30.05
Lessons from hereditary colorectal cancer. Cell (1996) 25.73
Role of histone H3 lysine 27 methylation in Polycomb-group silencing. Science (2002) 24.31
miR-15 and miR-16 induce apoptosis by targeting BCL2. Proc Natl Acad Sci U S A (2005) 21.51
Reduced expression of the let-7 microRNAs in human lung cancers in association with shortened postoperative survival. Cancer Res (2004) 18.86
Transcriptional repression by the methyl-CpG-binding protein MeCP2 involves a histone deacetylase complex. Nature (1998) 18.36
Dynamic regulation of nucleosome positioning in the human genome. Cell (2008) 15.60
Epigenetic differences arise during the lifetime of monozygotic twins. Proc Natl Acad Sci U S A (2005) 15.46
A genomic code for nucleosome positioning. Nature (2006) 15.38
Genome-scale identification of nucleosome positions in S. cerevisiae. Science (2005) 15.04
Inhibition of translational initiation by Let-7 MicroRNA in human cells. Science (2005) 13.84
EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells. Proc Natl Acad Sci U S A (2003) 13.68
Epigenetic reprogramming in mammalian development. Science (2001) 13.42
Genomic DNA methylation: the mark and its mediators. Trends Biochem Sci (2006) 13.32
The diverse functions of histone lysine methylation. Nat Rev Mol Cell Biol (2005) 12.70
Cancer epigenetics comes of age. Nat Genet (1999) 12.63
Comprehensive analysis of CpG islands in human chromosomes 21 and 22. Proc Natl Acad Sci U S A (2002) 12.33
Genome-wide analysis of Arabidopsis thaliana DNA methylation uncovers an interdependence between methylation and transcription. Nat Genet (2006) 11.88
Epigenetic gene silencing in cancer - a mechanism for early oncogenic pathway addiction? Nat Rev Cancer (2006) 11.22
Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat Rev Cancer (2006) 10.73
microRNAs as oncogenes and tumor suppressors. Dev Biol (2006) 10.68
A polycistronic microRNA cluster, miR-17-92, is overexpressed in human lung cancers and enhances cell proliferation. Cancer Res (2005) 10.46
Histone acetylation and transcriptional regulatory mechanisms. Genes Dev (1998) 10.16
Cellular differentiation, cytidine analogs and DNA methylation. Cell (1980) 10.15
The biology of chromatin remodeling complexes. Annu Rev Biochem (2009) 10.02
Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer. Nat Genet (1999) 9.53
Cancer/testis antigens, gametogenesis and cancer. Nat Rev Cancer (2005) 9.46
Hypomethylation distinguishes genes of some human cancers from their normal counterparts. Nature (1983) 9.28
Epigenetic inheritance at the agouti locus in the mouse. Nat Genet (1999) 9.14
5' CpG island methylation is associated with transcriptional silencing of the tumour suppressor p16/CDKN2/MTS1 in human cancers. Nat Med (1995) 9.10
Alterations in DNA methylation: a fundamental aspect of neoplasia. Adv Cancer Res (1998) 8.95
A gene hypermethylation profile of human cancer. Cancer Res (2001) 8.93
X inactivation, differentiation, and DNA methylation. Cytogenet Cell Genet (1975) 8.74
Aberrant CpG-island methylation has non-random and tumour-type-specific patterns. Nat Genet (2000) 8.58
A barrier nucleosome model for statistical positioning of nucleosomes throughout the yeast genome. Genome Res (2008) 7.89
Epigenetics in cancer. Carcinogenesis (2009) 7.49
Epigenetic modifications and human disease. Nat Biotechnol (2010) 7.29
MicroRNAs and cancer: short RNAs go a long way. Cell (2009) 7.25
A microRNA DNA methylation signature for human cancer metastasis. Proc Natl Acad Sci U S A (2008) 7.14
CpG island methylator phenotype in cancer. Nat Rev Cancer (2004) 7.13
Histone-deacetylase inhibitors: novel drugs for the treatment of cancer. Nat Rev Drug Discov (2002) 6.97
The microRNA miR-34a inhibits prostate cancer stem cells and metastasis by directly repressing CD44. Nat Med (2011) 6.85
The essentials of DNA methylation. Cell (1992) 6.72
Pharmacologic disruption of Polycomb-repressive complex 2-mediated gene repression selectively induces apoptosis in cancer cells. Genes Dev (2007) 6.71
Epigenetic reprogramming in mouse primordial germ cells. Mech Dev (2002) 6.67
Nucleosome positioning and gene regulation: advances through genomics. Nat Rev Genet (2009) 6.50
Gene body-specific methylation on the active X chromosome. Science (2007) 6.33
Covalent histone modifications--miswritten, misinterpreted and mis-erased in human cancers. Nat Rev Cancer (2010) 6.27
Regulation of the p27(Kip1) tumor suppressor by miR-221 and miR-222 promotes cancer cell proliferation. EMBO J (2007) 6.26
Methyltransferase recruitment and DNA hypermethylation of target promoters by an oncogenic transcription factor. Science (2002) 6.05
miR-21: a small multi-faceted RNA. J Cell Mol Med (2009) 5.59
Emerging molecular markers of cancer. Nat Rev Cancer (2002) 5.03
CpG islands influence chromatin structure via the CpG-binding protein Cfp1. Nature (2010) 4.86
Cancer epigenetics: modifications, screening, and therapy. Annu Rev Med (2008) 4.41
MicroRNA-122, a tumor suppressor microRNA that regulates intrahepatic metastasis of hepatocellular carcinoma. Hepatology (2009) 4.36
Developmental programming of CpG island methylation profiles in the human genome. Nat Struct Mol Biol (2009) 3.96
The role of let-7 in cell differentiation and cancer. Endocr Relat Cancer (2010) 3.95
Retracted A TARBP2 mutation in human cancer impairs microRNA processing and DICER1 function. Nat Genet (2009) 3.88
Relaxation of imprinted genes in human cancer. Nature (1993) 3.86
A polycomb repression signature in metastatic prostate cancer predicts cancer outcome. Cancer Res (2007) 3.82
Testicular germ-cell tumours in a broader perspective. Nat Rev Cancer (2005) 3.75
A robust methodology to study urine microRNA as tumor marker: microRNA-126 and microRNA-182 are related to urinary bladder cancer. Urol Oncol (2009) 3.59
MicroRNAs (miR)-221 and miR-222, both overexpressed in human thyroid papillary carcinomas, regulate p27Kip1 protein levels and cell cycle. Endocr Relat Cancer (2007) 3.53
The cancer epigenome--components and functional correlates. Genes Dev (2006) 3.40
5-methylcytosine, gene regulation, and cancer. Adv Cancer Res (1983) 3.27
Epigenetic gene silencing in cancer: the DNA hypermethylome. Hum Mol Genet (2007) 3.12
MicroRNAs and their target gene networks in breast cancer. Breast Cancer Res (2010) 2.83
Inactivation of the DNA repair gene O6-methylguanine-DNA methyltransferase by promoter hypermethylation is associated with G to A mutations in K-ras in colorectal tumorigenesis. Cancer Res (2000) 2.79
Induction of HDAC2 expression upon loss of APC in colorectal tumorigenesis. Cancer Cell (2004) 2.66
A compiled and systematic reference map of nucleosome positions across the Saccharomyces cerevisiae genome. Genome Biol (2009) 2.58
MicroRNA alterations in head and neck squamous cell carcinoma. Int J Cancer (2008) 2.56
The human let-7a-3 locus contains an epigenetically regulated microRNA gene with oncogenic function. Cancer Res (2007) 2.54
DNA methylation markers in colorectal cancer. Cancer Metastasis Rev (2010) 2.40
Preferential response of cancer cells to zebularine. Cancer Cell (2004) 2.39
A truncating mutation of HDAC2 in human cancers confers resistance to histone deacetylase inhibition. Nat Genet (2006) 2.33
Hypomethylation of a LINE-1 promoter activates an alternate transcript of the MET oncogene in bladders with cancer. PLoS Genet (2010) 2.27
DNA methylation as a therapeutic target in cancer. Clin Cancer Res (2007) 2.20
An evaluation of new criteria for CpG islands in the human genome as gene markers. Bioinformatics (2004) 2.19
Cancer epigenetics. CA Cancer J Clin (2010) 2.16
Trichostatin A is a histone deacetylase inhibitor with potent antitumor activity against breast cancer in vivo. Clin Cancer Res (2001) 2.15
Altered miRNA expression in sputum for diagnosis of non-small cell lung cancer. Lung Cancer (2009) 2.14
Inhibition of lysine-specific demethylase 1 by polyamine analogues results in reexpression of aberrantly silenced genes. Proc Natl Acad Sci U S A (2007) 2.11
Micromanagers of malignancy: role of microRNAs in regulating metastasis. Trends Genet (2008) 2.03
Hijacking the chromatin remodeling machinery: impact of SWI/SNF perturbations in cancer. Cancer Res (2009) 2.03
DNA global hypomethylation in squamous cell head and neck cancer associated with smoking, alcohol consumption and stage. Int J Cancer (2007) 1.97
Non-coding RNAs: Meet thy masters. Bioessays (2010) 1.90
Specific inhibition of DNMT1 by antisense oligonucleotides induces re-expression of estrogen receptor-alpha (ER) in ER-negative human breast cancer cell lines. Cancer Biol Ther (2003) 1.88
Formation of methylation patterns in the mammalian genome. Mutat Res (1997) 1.88
Exome sequencing of head and neck squamous cell carcinoma reveals inactivating mutations in NOTCH1. Science (2011) 11.12
Inactivation of LKB1/STK11 is a common event in adenocarcinomas of the lung. Cancer Res (2002) 7.09
BRAF mutation in papillary thyroid carcinoma. J Natl Cancer Inst (2003) 6.20
TP53 mutations and survival in squamous-cell carcinoma of the head and neck. N Engl J Med (2007) 5.92
Dysfunctional KEAP1-NRF2 interaction in non-small-cell lung cancer. PLoS Med (2006) 5.80
Association between BRAF V600E mutation and mortality in patients with papillary thyroid cancer. JAMA (2013) 5.71
Mutations in BRAF and KRAS characterize the development of low-grade ovarian serous carcinoma. J Natl Cancer Inst (2003) 5.64
BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer. J Clin Endocrinol Metab (2005) 4.39
Pharmacologic unmasking of epigenetically silenced tumor suppressor genes in esophageal squamous cell carcinoma. Cancer Cell (2002) 3.12
A pilot clinical study of treatment guided by personalized tumorgrafts in patients with advanced cancer. Mol Cancer Ther (2011) 2.74
Inverse relationship between human papillomavirus-16 infection and disruptive p53 gene mutations in squamous cell carcinoma of the head and neck. Clin Cancer Res (2008) 2.66
MicroRNA alterations in head and neck squamous cell carcinoma. Int J Cancer (2008) 2.56
The Human MitoChip: a high-throughput sequencing microarray for mitochondrial mutation detection. Genome Res (2004) 2.54
p53 mutations and survival in stage I non-small-cell lung cancer: results of a prospective study. J Natl Cancer Inst (2003) 2.54
DeltaNp63alpha and TAp63alpha regulate transcription of genes with distinct biological functions in cancer and development. Cancer Res (2003) 2.46
DNA methylation markers in colorectal cancer. Cancer Metastasis Rev (2010) 2.40
Quantitative detection of promoter hypermethylation of multiple genes in the tumor, urine, and serum DNA of patients with renal cancer. Cancer Res (2004) 2.34
Assembly and initial characterization of a panel of 85 genomically validated cell lines from diverse head and neck tumor sites. Clin Cancer Res (2011) 2.31
Somatic mutation and gain of copy number of PIK3CA in human breast cancer. Breast Cancer Res (2005) 2.20
Aquaporin 1 is overexpressed in lung cancer and stimulates NIH-3T3 cell proliferation and anchorage-independent growth. Am J Pathol (2006) 2.19
A quantitative promoter methylation profile of prostate cancer. Clin Cancer Res (2004) 2.06
Quantitation of promoter methylation of multiple genes in urine DNA and bladder cancer detection. J Natl Cancer Inst (2006) 2.05
Mitochondrial C-tract alteration in premalignant lesions of the head and neck: a marker for progression and clonal proliferation. Clin Cancer Res (2002) 1.97
Quantitative adenomatous polyposis coli promoter methylation analysis in tumor tissue, serum, and plasma DNA of patients with lung cancer. Cancer Res (2002) 1.88
Patient-derived xenografts for individualized care in advanced sarcoma. Cancer (2014) 1.82
Quantitative methylation-specific polymerase chain reaction gene patterns in urine sediment distinguish prostate cancer patients from control subjects. J Clin Oncol (2005) 1.80
Quantitative RARbeta2 hypermethylation: a promising prostate cancer marker. Clin Cancer Res (2004) 1.76
Inverse correlation between cyclin A1 hypermethylation and p53 mutation in head and neck cancer identified by reversal of epigenetic silencing. Cancer Res (2004) 1.74
Hypermethylation of Cyclin D2 is associated with loss of mRNA expression and tumor development in prostate cancer. J Mol Med (Berl) (2006) 1.72
Tumor-specific changes in mtDNA content in human cancer. Int J Cancer (2005) 1.70
Genome-wide promoter analysis uncovers portions of the cancer methylome. Cancer Res (2008) 1.70
Detection of aberrant methylation of four genes in plasma DNA for the detection of breast cancer. J Clin Oncol (2006) 1.69
Frequency and phenotypic implications of mitochondrial DNA mutations in human squamous cell cancers of the head and neck. Proc Natl Acad Sci U S A (2007) 1.68
Endothelin receptor type B gene promoter hypermethylation in salivary rinses is independently associated with risk of oral cavity cancer and premalignancy. Cancer Prev Res (Phila) (2010) 1.68
Selective growth inhibition in BRAF mutant thyroid cancer by the mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244. J Clin Endocrinol Metab (2007) 1.66
Electrophile and oxidant damage of mitochondrial DNA leading to rapid evolution of homoplasmic mutations. Proc Natl Acad Sci U S A (2003) 1.66
Gene promoter hypermethylation in tumors and lymph nodes of stage I lung cancer patients. Clin Cancer Res (2003) 1.65
Differential recognition of response elements determines target gene specificity for p53 and p63. Mol Cell Biol (2005) 1.63
Evaluation of promoter hypermethylation detection in body fluids as a screening/diagnosis tool for head and neck squamous cell carcinoma. Clin Cancer Res (2008) 1.62
Genome-wide genetic characterization of bladder cancer: a comparison of high-density single-nucleotide polymorphism arrays and PCR-based microsatellite analysis. Cancer Res (2003) 1.59
Fine mapping of chromosome 3 in uveal melanoma: identification of a minimal region of deletion on chromosomal arm 3p25.1-p25.2. Cancer Res (2003) 1.59
Global DNA hypomethylation is associated with in utero exposure to cotinine and perfluorinated alkyl compounds. Epigenetics (2010) 1.57
Mitochondrial subversion in cancer. Cancer Prev Res (Phila) (2011) 1.54
Detection of BRAF mutation on fine needle aspiration biopsy specimens: a new diagnostic tool for papillary thyroid cancer. J Clin Endocrinol Metab (2004) 1.54
Quantitative detection of Merkel cell virus in human tissues and possible mode of transmission. Int J Cancer (2010) 1.53
Real-time quantitative PCR demonstrates low prevalence of human papillomavirus type 16 in premalignant and malignant lesions of the oral cavity. Clin Cancer Res (2002) 1.53
Uncommon mutation, but common amplifications, of the PIK3CA gene in thyroid tumors. J Clin Endocrinol Metab (2005) 1.51
DeltaNp63 induces beta-catenin nuclear accumulation and signaling. Cancer Cell (2002) 1.51
Mutational analysis of BRAF in fine needle aspiration biopsies of the thyroid: a potential application for the preoperative assessment of thyroid nodules. Clin Cancer Res (2004) 1.47
OPCML is a broad tumor suppressor for multiple carcinomas and lymphomas with frequently epigenetic inactivation. PLoS One (2008) 1.47
Mouse mammary tumor-like env gene as a molecular marker for breast cancer? Int J Cancer (2002) 1.47
Mitochondrial D-loop mutations as clonal markers in multicentric hepatocellular carcinoma and plasma. Clin Cancer Res (2002) 1.46
Molecular assessment of lymph nodes in patients with resected stage I non-small cell lung cancer: preliminary results of a prospective study. J Thorac Cardiovasc Surg (2002) 1.46
Involvement of aquaporins in colorectal carcinogenesis. Oncogene (2003) 1.45
Feasibility of quantitative PCR-based saliva rinse screening of HPV for head and neck cancer. Int J Cancer (2005) 1.45
DeltaNp63alpha up-regulates the Hsp70 gene in human cancer. Cancer Res (2005) 1.44
Changes in CpG islands promoter methylation patterns during ductal breast carcinoma progression. Cancer Epidemiol Biomarkers Prev (2009) 1.43
Mitochondrial cytochrome B gene mutation promotes tumor growth in bladder cancer. Cancer Res (2008) 1.41
An oligonucleotide microarray for high-throughput sequencing of the mitochondrial genome. J Mol Diagn (2006) 1.40
An EGFR-ERK-SOX9 signaling cascade links urothelial development and regeneration to cancer. Cancer Res (2011) 1.37
N-methyl-D-aspartate receptor type 2B is epigenetically inactivated and exhibits tumor-suppressive activity in human esophageal cancer. Cancer Res (2006) 1.36
Early occurrence of RASSF1A hypermethylation and its mutual exclusion with BRAF mutation in thyroid tumorigenesis. Cancer Res (2004) 1.35
PGP9.5 promoter methylation is an independent prognostic factor for esophageal squamous cell carcinoma. Cancer Res (2005) 1.34
Detection of promoter hypermethylation of multiple genes in the tumor and bronchoalveolar lavage of patients with lung cancer. Clin Cancer Res (2004) 1.32
RACK1 and stratifin target DeltaNp63alpha for a proteasome degradation in head and neck squamous cell carcinoma cells upon DNA damage. Cell Cycle (2004) 1.31
Promoter hypermethylation as an independent prognostic factor for relapse in patients with prostate cancer following radical prostatectomy. Clin Cancer Res (2005) 1.30
High promoter methylation levels of APC predict poor prognosis in sextant biopsies from prostate cancer patients. Clin Cancer Res (2007) 1.30
Aberrant promoter methylation of multiple genes during pathogenesis of bladder cancer. Cancer Epidemiol Biomarkers Prev (2008) 1.30
BRAF mutations in anaplastic thyroid carcinoma: implications for tumor origin, diagnosis and treatment. Mod Pathol (2004) 1.27
Genetic and epigenetic screening for gene alterations of the chromatin-remodeling factor, SMARCA4/BRG1, in lung tumors. Genes Chromosomes Cancer (2004) 1.27
Lack of BRAF mutation in primary uveal melanoma. Invest Ophthalmol Vis Sci (2003) 1.26
Identification of hypermethylated genes associated with cisplatin resistance in human cancers. Cancer Res (2010) 1.26
KIF1A and EDNRB are differentially methylated in primary HNSCC and salivary rinses. Int J Cancer (2010) 1.26
Differential DNA hypermethylation of critical genes mediates the stage-specific tobacco smoke-induced neoplastic progression of lung cancer. Clin Cancer Res (2005) 1.26
Role of human aquaporin 5 in colorectal carcinogenesis. Am J Pathol (2008) 1.25
Overexpression of c-met as a prognostic indicator for transitional cell carcinoma of the urinary bladder: a comparison with p53 nuclear accumulation. J Clin Oncol (2002) 1.24
Ribonucleases as a novel pro-apoptotic anticancer strategy: review of the preclinical and clinical data for ranpirnase. Cancer Invest (2005) 1.24
Assessment of gene promoter hypermethylation for detection of cervical neoplasia. Int J Cancer (2006) 1.23
P63 alpha mutations lead to aberrant splicing of keratinocyte growth factor receptor in the Hay-Wells syndrome. J Biol Chem (2003) 1.23
Overexpression of AQP5, a putative oncogene, promotes cell growth and transformation. Cancer Lett (2008) 1.23
Deleted in colorectal cancer is a putative conditional tumor-suppressor gene inactivated by promoter hypermethylation in head and neck squamous cell carcinoma. Cancer Res (2006) 1.22
Prioritizing phase I treatment options through preclinical testing on personalized tumorgraft. J Clin Oncol (2011) 1.21
Mitochondrial DNA content increase in response to cigarette smoking. Cancer Epidemiol Biomarkers Prev (2006) 1.20
Methylation of the thyroid-stimulating hormone receptor gene in epithelial thyroid tumors: a marker of malignancy and a cause of gene silencing. Cancer Res (2003) 1.20
Exon 15 BRAF mutations are uncommon in melanomas arising in nonsun-exposed sites. Clin Cancer Res (2004) 1.19
Molecular analysis of plasma DNA for the early detection of lung cancer by quantitative methylation-specific PCR. Clin Cancer Res (2010) 1.18
DeltaNp63alpha levels correlate with clinical tumor response to cisplatin. Cell Cycle (2005) 1.18
MT1G hypermethylation is associated with higher tumor stage in prostate cancer. Cancer Epidemiol Biomarkers Prev (2005) 1.18
Absence of V599E BRAF mutations in desmoplastic melanomas. Cancer (2005) 1.17
Expression of aquaporin 5 (AQP5) promotes tumor invasion in human non small cell lung cancer. PLoS One (2008) 1.17
Aquaporin expression in human lymphocytes and dendritic cells. Am J Hematol (2004) 1.17
High-throughput molecular analysis of urine sediment for the detection of bladder cancer by high-density single-nucleotide polymorphism array. Cancer Res (2003) 1.16
Activation of the NOTCH pathway in head and neck cancer. Cancer Res (2013) 1.15
CDC91L1 (PIG-U) is a newly discovered oncogene in human bladder cancer. Nat Med (2004) 1.14
An epigenetic marker panel for detection of lung cancer using cell-free serum DNA. Clin Cancer Res (2011) 1.13
Efficacy of weekly docetaxel and bevacizumab in mesenchymal chondrosarcoma: a new theranostic method combining xenografted biopsies with a mathematical model. Cancer Res (2008) 1.12
Targeting of mutant hogg1 in mammalian mitochondria and nucleus: effect on cellular survival upon oxidative stress. BMC Cancer (2006) 1.12
Regulation of p53 family member isoform DeltaNp63alpha by the nuclear factor-kappaB targeting kinase IkappaB kinase beta. Cancer Res (2010) 1.11
Mitochondrial DNA as a cancer biomarker. J Mol Diagn (2005) 1.11
Quantitative GSTP1 hypermethylation in bodily fluids of patients with prostate cancer. Urology (2002) 1.11